Skip to main content

stock

CTOR · CITIUS ONCOLOGY, INC.

What CITIUS ONCOLOGY, INC. reports to the SEC, read from its filings.

Open in the app

Price

The live CTOR price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on CTOR.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
92,981,204 as of 2026-08-13 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
-114.1%
ROA
-41.1%

Health

Current ratio
0.7x
Debt/equity
—

Deep value

NCAV
-$29.00M
NCAV per share
-$0.31
Price/NCAV
Locked
NNWC
-$43.32M
NNWC per share
-$0.47
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenueGross profitOperating incomeNet incomeFiling
2026-06-30$1.49M$1.00M-$8.72M-$8.92M
10-Q filed 2026-08-14
2026-03-31$1.67M$1.34M-$28.61M-$26.61M
10-Q filed 2026-08-14
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31$3.94M$3.15M-$5.25M-$5.53M
10-Q filed 2026-08-14
Assembled from more than one filing; the filing above is only the newest of them.
2025-09-30——-$4.71M-$5.00M
10-K filed 2025-12-23
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-06-30——-$4.94M-$5.37M
10-Q filed 2026-08-14
2025-03-31——-$7.47M-$7.74M
10-Q filed 2026-08-14
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31——-$6.39M-$6.66M
10-Q filed 2026-08-14
Assembled from more than one filing; the filing above is only the newest of them.
2024-09-30———-$6.81M
10-K filed 2025-12-23
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
Assets
$112.09M
Equity
$40.38M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-09-30—-$23.52M-$24.76M—
2024-09-30—-$20.57M-$21.15M—
2023-12-31—-$1.01M$2.42M—
2023-09-30——-$12.70M—
2022-12-31—-$138,115$380,811—

Company filings

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named CTOR, and the market events around them.

Sign in to see this

Board

The CTOR board could not be loaded.

Retry the CTOR board

nakagai

Signals on CTOR come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the CTOR board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

CITIUS ONCOLOGY, INC. (CTOR): SEC filings, financials and insider trades · Nakagai